Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release nalbuphine formulation targeting chronic cough associated with IPF, non-IPF ILD, and refractory chronic cough. Leveraging opioid receptor modulation, it aims to address unmet medical needs with potential advantages over existing therapies. The company focuses on clinical development, regulatory approval, and commercialization, competing with other innovative treatments in respiratory and dermatologic indications.
This description was generated via AI from an annual report. Updated about 1 year ago.